TET2 and acute myeloid leukemia: Treatment with the hypomethylating agents’ showed efficacy in myelodysplastic syndrome and acute myeloid leukemia, a response that appears to correlate with IDH1/2, TET2, and DNMT3A mutations [64,65,66].